IKK Gamma is a protein. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.
| Gene | [IKBKG](/genes/ikbkg) (NEMO) |
|---|
| UniProt ID | [Q9Y6K9](https://www.uniprot.org/uniprot/Q9Y6K9) |
|---|
| PDB Structures | 3CL3, 4BWB, 5ZFV |
|---|
| Molecular Weight | 48,593 Da |
|---|
| Subcellular Localization | Cytoplasm, Cell membrane, Nucleus |
|---|
| Protein Family | [NF-kB](/entities/nf-kb) essential modulator family |
|---|
IKK Gamma (also known as NEMO - NF-kB Essential Modulator) is the regulatory subunit of the IKK (IkappaB kinase) complex. It serves as a scaffold and regulatory protein essential for NF-kB activation.
The protein contains:
- N-terminal region: binds IKKα and IKKβ kinases
- C-terminal region: contains coiled-coil domain and leucine zipper
- Zinc finger domain: essential for signaling
- NEMO oligomerization domain: mediates higher-order complex formation
NEMO forms a heterotrimeric complex with IKKα and IKKβ catalytic subunits.
IKK Gamma/NEMO is critical for NF-kB signaling in the nervous system:
- NF-kB Activation: Essential for canonical NF-kB pathway activation in response to cytokines, stress, and pathogens
- Neuronal Survival: NF-kB-mediated transcription promotes neuronal survival and plasticity
- Synaptic Plasticity: NF-kB regulates AMPA receptor trafficking and synaptic strength
- Neuroinflammation: Controls inflammatory gene expression in microglia and astrocytes
- Myelination: NF-kB signaling regulates oligodendrocyte differentiation and myelination
IKK/NEMO signaling is dysregulated in several neurodegenerative diseases:
- Chronic neuroinflammation via NF-kB hyperactivation
- Elevated IKK activity in AD brains
- Pro-inflammatory cytokine production (IL-1β, TNF-α)
- Amyloid-beta potentiates NF-kB activation
- Therapeutic target: IKKβ inhibitors in development
- NF-kB activation in dopaminergic neurons
- Neuroinflammation in substantia nigra
- Mitochondrial toxins (MPTP, 6-OHDA) activate IKK/NF-kB pathway
- Glial cell activation contributes to neurodegeneration
- NF-kB activation in motor neurons and gliosis
- Pro-inflammatory environment in ALS
- Mutations in IKBKG cause X-linked incompatibilities
¶ Stroke and Brain Ischemia
- Reperfusion injury triggers NF-kB activation
- IKK/NF-kB mediates excitotoxic cell death
- Therapeutic potential for IKK inhibitors
- Demyelination involves NF-kB signaling
- T-cell activation requires NF-kB
- Therapeutic targeting in development
Targeting IKK/NF-kB pathway:
- IKK Inhibitors: Small molecule inhibitors (e.g., MLN120B, Bay 11-7082) in development
- NF-kB Decoys: Gene therapy approaches
- Anti-inflammatory Strategies: Reduce upstream inflammatory triggers
- Blood-Brain Barrier Permeable Compounds: For CNS delivery
¶ Drug Candidates
- IMD-0354: IKKβ inhibitor, neuroprotective in AD models
- PS-1145: IKK inhibitor, reduces neuroinflammation
- Minocycline: Indirectly inhibits NF-kB, tested in ALS and stroke
- Mattson et al., NF-kB in neuronal survival and degeneration (2005)
- Kaltschmidt et al., NF-kB in synaptic plasticity (2007)
- Camandola et al., NF-kB activation in Alzheimer's disease (2007)
- Ghosh et al., IKK complex and NF-kB signaling (2012)
- Hutti et al., IKKgamma mutations and immunodeficiency (2004)
- NF-kB Signaling Pathway
- Neuroinflammation in AD
- Parkinson's Disease Neuroinflammation